Single-Dose Safety and Pharmacokinetics of Amprenavir (141W94), a Human Immunodeficiency Virus Type 1 (HIV-1) Protease Inhibitor, in HIV-Infected Children

A phase I, open-label, dose-escalating trial was conducted to evaluate the safety, tolerability, and pharmacokinetics of single, oral doses of amprenavir (141W94), a potent inhibitor of human immunodeficiency virus type 1 (HIV-1) protease, in 20 HIV-infected children 4 to 12 years of age. The doses...

Full description

Saved in:
Bibliographic Details
Main Authors: Yogev, Ram, Kovacs, Andrea, Chadwick, Ellen G., Homans, James D., Lou, Yu, Symonds, William T.
Format: Artigo
Language:Inglês
Published: American Society for Microbiology 2005
Subjects:
Antiviral Agents
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC538869/
https://ncbi.nlm.nih.gov/pubmed/15616313
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.49.1.336-341.2005
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items